Insulin-Like Growth Factor I (IGF-1)

A well-characterized basic peptide believed to be secreted by the liver and to circulate in the blood. It has growth-regulating, insulin-like, and mitogenic activities. This growth factor has a major, but not absolute, dependence on GROWTH HORMONE. It is believed to be mainly active in adults in contrast to INSULIN-LIKE GROWTH FACTOR II, which is a major fetal growth factor.

Also Known As:

Networked: 13099 relevant articles (663 outcomes, 2163 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Frystyk, Jan: 64 articles (08/2020 - 08/2002)
2.	Colao, Annamaria: 61 articles (01/2020 - 03/2002)
3.	Kaaks, Rudolf: 58 articles (06/2022 - 03/2002)
4.	Pollak, Michael: 50 articles (01/2022 - 07/2002)
5.	Colao, A: 49 articles (08/2022 - 01/2000)
6.	Pollak, Michael N: 45 articles (06/2022 - 07/2002)
7.	Flyvbjerg, Allan: 44 articles (01/2018 - 08/2002)
8.	Rinaldi, Sabina: 40 articles (01/2019 - 03/2002)
9.	Clemmons, David R: 40 articles (01/2017 - 03/2002)
10.	Ghigo, E: 39 articles (05/2022 - 01/2000)

Related Diseases

1.	Acromegaly 01/01/2020 - "Random GH and IGF-1 after surgery were lower in the first group (p < 0.05) CONCLUSIONS: Changes in the Romanian protocol and highly specialised pituitary centres has improved the cure rate and disease control in patients with acromegaly." 01/01/2020 - "IGF-I levels ≤ 1.25-fold ULN 3 months after TSS was the best guide for long-term remission in acromegaly patients with both initial surgical failure and discrepant biochemical results." 06/01/2019 - "While current treatment modalities have greatly improved prognoses for most patients, a significant number present clinical symptoms of acromegaly with elevated levels of IGF-1 in the absence of increased GH levels, a phenomenon known as micromegaly. " 01/01/2011 - "The results of the second postoperative week, 3 months postoperative, and the most recent follow-up OGTT and IGF-1 measurements were used to calculate the positive and negative predictive values of the following endocrinological criteria of acromegaly remission: the common consensus criteria for acromegaly remission, GH suppression to < 1 μg/l during OGTT and IGF-1 within normal limits. " 03/01/1987 - "The clinical and metabolic parameters of acromegaly dramatically improved in all patients whose plasma GH and somatomedin-C levels decreased even if they were not normalized by SMS. "
2.	Insulin Resistance 01/01/2016 - "The improvement in homeostasis model assessment for insulin resistance (HOMA-IR) was best predicted by the decreases in IGF-I and vaspin and the lack of an increase in trunk fat (R2 = 0.59, p = 0.001). " 04/01/2005 - "This study shows that cardiac indices, insulin resistance and body composition were not different between patients with complete biochemical remission and those with discordant GH and IGF-I levels. " 02/01/2023 - "When categorized according to liver status, IGF-1 increased significantly in children with MAFLD (P = 0.008) and tended to increase in children without MAFLD (P = 0.052).   Conclusions: Ten weeks of lifestyle intervention decreased insulin resistance and improved the IGF axis. " 01/01/2020 - "In conclusion, increasing IGF-1 levels was beneficial for body composition but detrimental with respect to insulin resistance. " 05/01/2005 - "In non-GHD subjects, 12 months of GH treatment withdrawal significantly decreased IGF-I levels, IMT (to 0.54 +/- 0.06 mm; P < 0.001 vs. baseline), systolic and diastolic peak velocities, and improved insulin resistance. "
3.	Neoplasms (Cancer) 09/01/2018 - "There was no endocrinologic remission by surgery alone for type D tumors; nevertheless, compared with type C tumors, type D tumors showed marked reductions in the postoperative nadir of GH at 1 week, 6 months, and 1 year and of insulin-like growth factor I at 1 year. " 01/01/2017 - "Unlike in congenital IGF-1 deficiency, there is no complete protection against cancer in GHD patients. " 12/01/2020 - "Univariate and multivariate analysis demonstrated that tumor sizes before RT, pre-RT IGF-1 level, and age significant predicted the endocrine remission. " 04/01/2004 - "Overall recurrence risk was significantly greater for tumors that expressed IGF-I-R (p = 0.05) but only approached statistical significance (p = 0.08) when disease-free survival was determined. " 01/01/2022 - "insulin-like growth factor-I binding protein-2 and -3 levels and improved the discrimination of a standard reference model for the prediction of recurrence-free survival, cancer-specific survival, and overall survival (+4.9%, 4.9%, 2.3%, respectively). "
4.	Body Weight (Weight, Body) 12/01/2007 - "Disruption of local IGF-I dramatically reduced body weight 28-37%, femur areal bone mineral density 10-25%, and femur bone size 18-24% in growing mice. " 02/01/2003 - "In IGF-I-treated rats, serum concentration of IGF-I and final body weight were significantly greater because of a proportionate increase in carcass lean body mass than in vehicle-treated rats. " 01/01/1995 - "The reduction of GH secretion was associated with a decreased body weight and a significant reduction in plasma IGF-I concentration. " 09/01/1992 - "The genetic line of nervous dogs had significantly greater scores of fearfulness, lower total body weights, lower weight/height ratio, and lower serum IGF-I levels than the normal line of pointer dogs. " 06/05/1986 - "After this 7 day administration of IGF-I, the body weight increased to 197.6 +/- 3.5% of initial values; the value was significantly greater than that of the control (179.4 +/- 3.7% of initial values, P less than 0.01). "
5.	Type 2 Diabetes Mellitus (MODY) 07/01/2006 - "We have recently reported that Pdx1-Cre-mediated whole pancreas inactivation of IGF-I gene [in pancreatic-specific IGF-I gene-deficient (PID) mice] results in increased beta-cell mass and significant protection against both type 1 and type 2 diabetes. " 11/30/1997 - "Maximal IGF-I binding was significantly greater in NIDDM patients than controls and was positively correlated with the percentage of hybrids whereas IGF-I binding affinity did not differ between the two groups. " 02/01/2005 - "This suggests that the local prosclerotic IGF-I system is activated in type 2 diabetes and diminishes ER-mediated protection against GS. " 01/01/2020 - "This study found evidence that increased IGF-1 levels may be causally associated with higher risk of type 2 diabetes. " 11/01/2018 - "This study showed for the first time that combined evaluation by serum insulin-like growth factor-I and BMD is useful to assess the risk of vertebral fracture in postmenopausal women and men with type 2 diabetes. "

Related Drugs and Biologics

1.	Insulin-Like Growth Factor I (IGF-1)
2.	Insulin (Novolin)
3.	Growth Hormone (Somatotropin)
4.	Glucose (Dextrose)
5.	Insulin-Like Growth Factor Binding Protein 3
6.	Proteins (Proteins, Gene)
7.	pegvisomant
8.	Insulin-Like Peptides
9.	Somatostatin (Somatotropin Release-Inhibiting Factor)
10.	Insulin-Like Growth Factor II (Somatomedin A)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Glycemic Control
4.	Injections
5.	Radiotherapy